Production (Stage)
Ernexa Therapeutics Inc.
ERNA
$2.29
-$0.08-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.00K | 487.00K | 47.00K | 47.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.00K | 487.00K | 47.00K | 47.00K |
| Cost of Revenue | -- | 0.00 | -60.00K | 95.00K | 61.00K |
| Gross Profit | -- | 1.00K | 547.00K | -48.00K | -14.00K |
| SG&A Expenses | 1.42M | 1.73M | 3.38M | 3.90M | 4.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.73M | 2.70M | 4.32M | 4.98M | 5.83M |
| Operating Income | -2.73M | -2.70M | -3.84M | -4.93M | -5.79M |
| Income Before Tax | -8.19M | -5.75M | -26.59M | -5.53M | -6.64M |
| Income Tax Expenses | 8.00K | 11.00K | 12.00K | 3.00K | 4.00K |
| Earnings from Continuing Operations | -8.20M | -5.76M | -26.60M | -5.53M | -6.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.20M | -5.76M | -26.60M | -5.53M | -6.65M |
| EBIT | -2.73M | -2.70M | -3.84M | -4.93M | -5.79M |
| EBITDA | -2.71M | -2.68M | -3.80M | -4.89M | -5.75M |
| EPS Basic | -2.31 | -2.26 | -73.76 | -15.35 | -18.43 |
| Normalized Basic EPS | -1.44 | -1.65 | -9.93 | -9.69 | -11.51 |
| EPS Diluted | -2.31 | -2.26 | -73.76 | -15.35 | -18.43 |
| Normalized Diluted EPS | -1.44 | -1.65 | -9.93 | -9.69 | -11.51 |
| Average Basic Shares Outstanding | 3.56M | 2.56M | 360.70K | 360.70K | 360.70K |
| Average Diluted Shares Outstanding | 3.56M | 2.56M | 360.70K | 360.70K | 360.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 0.00% | -0.14% | -- |